# Treatment of Delayed Hypersensitivity After Injection of Nasal Fillers

**Authors:** Liya Jiang, Fei Chen, Meiyang He, Yuejie Zhou, Qingqian Wei, Jintian Hu

PMC · DOI: 10.1111/jocd.16681 · 2024-12-08

## TL;DR

This paper presents a treatment for nasal filler complications using a drug combination that safely reduces swelling and deformity.

## Contribution

A novel intralesional drug regimen combining triamcinolone acetonide, 5-fluorouracil, and lidocaine is proposed for filler-related hypersensitivity.

## Key findings

- Swelling and sclerosis disappeared within 44.5 ± 2.12 days after three treatments.
- No infections or adverse effects were observed during the 6-month follow-up.
- The drug combination showed safety and effectiveness in treating delayed filler hypersensitivity.

## Abstract

Soft tissue filler injection is the second most commonly performed cosmetic procedure worldwide, with augmentation rhinoplasty being the most common filling surgery in Asian countries because Asians predominantly have a low nasal bridge. With the increasing pursuit of beauty, the adverse reactions after injection not only damage the patient's appearance but also greatly affect their quality of life. Therefore, exploring effective methods to address adverse reactions after nasal filler injections is necessary.

Herein, we aimed to explore safe and effective drug doses and concentrations for the treatment of two patients who developed an allergic reaction after a nasal filling by intralesional drug injection.

Two patients developed severe swelling and deformity of the nose after the injection of fillers 6 months to 1 year prior to presentation. High‐frequency ultrasound and local conditions revealed inflammation in the injected area. The patients were administered the combination of 0.7% triamcinolone acetonide, 0.42% 5‐fluorouracil, and 0.7% lidocaine into the affected area; they were followed up for 6 months.

After three times of treatment, swelling and sclerosis disappeared after 44.5 ± 2.12 days. No adverse effects of the infections were observed.

This drug regimen may represent a safe and effective therapeutic strategy for the treatment of complications after soft tissue filler injections.

## Linked entities

- **Chemicals:** triamcinolone acetonide (PubChem CID 6436), 5-fluorouracil (PubChem CID 3385), lidocaine (PubChem CID 3676)
- **Diseases:** allergic reaction (MONDO:0000605)

## Full-text entities

- **Diseases:** infections (MESH:D007239), Delayed Hypersensitivity (MESH:D006968), allergic reaction (MESH:D004342), deformity of the nose (MESH:D009668), inflammation (MESH:D007249), swelling (MESH:D004487), sclerosis (MESH:D012598)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11845941/full.md

---
Source: https://tomesphere.com/paper/PMC11845941